Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Trials, Inc

Neither a doctor nor a teaching hospital

Research payments

$107,044

27 payments

Through program year 2025, Clinical Trials, Inc is reported as receiving $107,044 in research payments, across 27 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $40 1
2022 Research $65,181 4
2021 Research $20,426 14
2020 Research $14,059 4
2019 Research $7,338 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ucb SA $81,890 18 payments
  2. UCB Biosciences Inc. $17,319 4 payments
  3. Sunovion Pharmaceuticals Inc. $7,835 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, open-label study to evaluate the pharmacokinetics, Tolerability, and Safety of a Single dose of staccato alprazolam in adolescent STUDY participants with epilepsy $68,019 7 payments
  2. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures $13,306 8 payments
  3. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide As Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clo $8,582 2 payments
  4. An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease $7,338 4 payments
  5. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide As Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic $5,024 1 payment
  6. An Open-Label, Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Lacosamide As Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy Phase 3 $3,713 1 payment
  7. Study name not reported $497 1 payment
  8. A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal Onset Seizures in Adult $453 1 payment
  9. An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizu $103 1 payment
  10. An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures $9 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record